Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Syros Pharmaceuticals, Inc. (SYRS) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz and Grossman, has launched an investigation into Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) on behalf of shareholders. The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen treating acute myeloid leukemia (AML). This decision was based on a prespecified interim analysis indicating a low probability of success in demonstrating superiority at the final analysis.
Investors who purchased Syros securities are encouraged to participate in the investigation. The law firm is offering its services on a contingency fee basis, meaning fees will only be charged if the case is successful. Bronstein, Gewirtz & Grossman, has a track record of recovering significant sums for investors in securities fraud class actions and shareholder derivative suits.
Bronstein, Gewirtz e Grossman hanno avviato un'indagine nei confronti di Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) per conto degli azionisti. L'indagine segue l'annuncio di Syros del 12 agosto 2024, relativo alla decisione di interrompere l'arruolamento nel SELECT-AML-1 studio clinico di Fase 2 per un regime di tripletto nel trattamento della leucemia mieloide acuta (LMA). Questa decisione è stata presa in base a un'analisi intermedia predefinita che ha indicato una bassa probabilità di successo nel dimostrare la superiorità nell'analisi finale.
Si incoraggiano gli investitori che hanno acquistato titoli Syros a partecipare all'indagine. Lo studio legale offre i suoi servizi su base di pagamento condizionato, il che significa che le spese saranno addebitate solo se il caso avrà successo. Bronstein, Gewirtz & Grossman ha un comprovato track record nel recupero di sommi significative per gli investitori in azioni legali per frodi sui titoli e cause derivate dagli azionisti.
Bronstein, Gewirtz y Grossman han lanzado una investigación sobre Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) en nombre de los accionistas. La investigación sigue al anuncio de Syros el 12 de agosto de 2024, sobre la decisión de interrumpir la inscripción en el ensayo clínico SELECT-AML-1 de Fase 2 para un régimen de triplete que trata la leucemia mieloide aguda (LMA). Esta decisión se basó en un análisis intermedio preestablecido que indicaba una baja probabilidad de éxito en la demostración de superioridad en el análisis final.
Se anima a los inversores que compraron valores de Syros a participar en la investigación. El bufete de abogados ofrece sus servicios en base a honorarios contingentes, lo que significa que solo se cobrarán si el caso tiene éxito. Bronstein, Gewirtz & Grossman tiene un historial comprobado de recuperación de sumas significativas para los inversores en acciones colectivas por fraude de valores y demandas derivadas de los accionistas.
브론스타인, 게윗츠 및 그로스만은 Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)에 대해 주주를 대신하여 조사를 시작했습니다. 이 조사는 Syros가 2024년 8월 12일에 급성 골수성 백혈병(AML)을 치료하는 트리플 요법에 대한 SELECT-AML-1 2상 임상시험에서 등록을 중단하겠다고 발표한 뒤 진행됩니다. 이 결정은 최종 분석에서 우월성을 입증할 가능성이 낮다는 것을 나타내는 사전 지정된 중간 분석을 바탕으로 했습니다.
Syros 증권을 매입한 투자자들은 조사에 참여할 것을 권장합니다. 이 법률 사무소는 사건이 성공할 경우에만 수수료를 청구하는 조건부 수수료 기반으로 서비스를 제공합니다. 브론스타인, 게윗츠 & 그로스만은 증권 사기 집단 소송 및 주주 파생 소송에서 투자자를 위한 상당한 금액을 회수한 경력이 있습니다.
Bronstein, Gewirtz et Grossman ont lancé une enquête concernant Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) au nom des actionnaires. L'enquête fait suite à l'annonce de Syros le 12 août 2024, annonçant qu'elle mettra fin à l'inscription dans l'
Les investisseurs ayant acheté des titres Syros sont encouragés à participer à l'enquête. Le cabinet d'avocats propose ses services sur une base de frais conditionnels, ce qui signifie que des frais ne seront facturés que si le cas est couronné de succès. Bronstein, Gewirtz & Grossman a un historique de récupération de sommes significatives pour les investisseurs dans le cadre d'actions collectives pour fraude sur titres et de poursuites dérivées des actionnaires.
Bronstein, Gewirtz und Grossman haben eine Untersuchung gegen Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) im Namen der Aktionäre eingeleitet. Die Untersuchung folgt auf die Ankündigung von Syros am 12. August 2024, dass die Rekrutierung für die SELECT-AML-1 Phase 2 klinische Studie zu einem Triplettherapieansatz zur Behandlung der akuten myeloischen Leukämie (AML) eingestellt wird. Diese Entscheidung basierte auf einer vorab festgelegten Zwischenanalyse, die eine geringe Wahrscheinlichkeit des Erfolgs bei der Demonstration der Überlegenheit in der Abschlussanalyse anzeigte.
Investoren, die Syros-Wertpapiere erworben haben, werden ermutigt, an der Untersuchung teilzunehmen. Die Kanzlei bietet ihre Dienste auf Honorarbasis an, was bedeutet, dass Gebühren nur erhoben werden, wenn der Fall erfolgreich ist. Bronstein, Gewirtz & Grossman hat eine Erfolgsbilanz bei der Rückgewinnung signifikanter Beträge für Investoren in Wertpapierbetrugs-Klageverfahren und Aktionärsderivate.
- None.
- Discontinuation of SELECT-AML-1 Phase 2 clinical trial enrollment
- Low probability of success in demonstrating superiority for AML treatment
- Potential legal claims against the company
- Possible negative impact on investor confidence and stock value
Insights
This investigation by Bronstein, Gewirtz & Grossman, into Syros Pharmaceuticals raises significant legal and financial concerns. The firm's focus on the discontinuation of the SELECT-AML-1 Phase 2 clinical trial suggests potential securities fraud or misrepresentation. This could lead to a class action lawsuit, impacting shareholder value and the company's market position.
The key issue is whether Syros adequately disclosed risks associated with the trial or if there was any misleading information provided to investors. The timing and nature of the trial's discontinuation will be important in determining if there were any breaches of fiduciary duty or violations of securities laws. Investors should closely monitor this situation as it could result in financial settlements or regulatory actions against Syros.
The discontinuation of Syros' SELECT-AML-1 Phase 2 trial is a significant setback for the company's oncology pipeline. The trial was evaluating a triplet regimen for acute myeloid leukemia (AML), a challenging area in hematology-oncology. The decision to halt enrollment based on a prespecified interim analysis indicates that the treatment's efficacy fell short of expectations.
This outcome may have broader implications for Syros' gene control platform and its approach to targeting RARA gene overexpression in AML. It raises questions about the viability of their scientific approach and could impact investor confidence in the company's other pipeline candidates. The failure of this trial might necessitate a strategic reevaluation of Syros' research focus and resource allocation in oncology drug development.
The announcement of the clinical trial discontinuation and subsequent legal investigation could have severe financial repercussions for Syros Pharmaceuticals. This news is likely to cause a significant drop in stock price, potentially triggering a
Investors should be prepared for increased volatility and potential liquidity issues if the legal investigation progresses to a full-blown lawsuit. The company may face increased costs related to legal defense and potential settlements. Moreover, this setback could hinder future fundraising efforts, which are important for clinical-stage biotech companies. Syros may need to reevaluate its cash burn rate and potentially consider strategic alternatives to ensure long-term viability.
NEW YORK CITY, NY / ACCESSWIRE / August 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ:SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Investigation Details
On August 12, 2024, Syros issued a press release "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." According to the Company, the "decision is based on the results of a prespecified interim analysis of the trial," and its analysis that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low."
What's Next?
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
View the original press release on accesswire.com
FAQ
What is the reason for the investigation into Syros Pharmaceuticals (SYRS)?
What was the SELECT-AML-1 Phase 2 clinical trial by Syros Pharmaceuticals (SYRS) studying?
How can shareholders participate in the investigation of Syros Pharmaceuticals (SYRS)?
What are the potential consequences of the investigation for Syros Pharmaceuticals (SYRS)?
